Zobrazeno 1 - 10
of 414
pro vyhledávání: '"L. Euller-Ziegler"'
Publikováno v:
Journal Français d'Ophtalmologie. 41:350-356
Resume Objectif Decrire les caracteristiques des cas d’uveite survenant au cours d’une biotherapie et/ou un traitement par disease-modifying antirheumatic drug (DMARD) rapportes dans la base de pharmacovigilance. Methodes La base de donnees natio
Autor:
Francis Guillemin, A.-C. Rat, E. Verrouil, P. Fardellone, L. Euller-Ziegler, Joël Coste, Bruno Fautrel, Jacques Pouchot, Bernard Mazières, Alain Saraux, C. Roux
Publikováno v:
BONE
BONE, Elsevier, 2018, 107, pp.143-144. ⟨10.1016/j.bone.2017.11.017⟩
BONE, Elsevier, 2018, 107, pp.143-144. ⟨10.1016/j.bone.2017.11.017⟩
International audience
Publikováno v:
Journal francais d'ophtalmologie. 41(4)
To report the characteristics of uveitis cases occurring while on biologic therapy or disease-modifying antirheumatic drugs (DMARDs) reported to the French national pharmacovigilance database.All the uveitis cases occurring in patients with chronic r
Publikováno v:
Poster Presentations.
Background The relationship between oxytocine (OT) and osteoarthritis (OA) is poorly studied and remains unknown. However the subchondral bone is considered as a major player in osteoarthritis, and a protective effect of OT on bone mineralization is
Autor:
L. Euller Ziegler
Publikováno v:
Abstracts Accepted for Publication.
Background Managing the increasing burden of chronic diseases is a major public health problem. Are early diagnosis and management a key point for their optimal care and outcome? Objectives Assessing early diagnosis and management of chronic diseases
Autor:
C. Beauvais, T. Schaeverbeke, Emmanuelle Dernis, S. Pouplin, Isabelle Chary-Valckenaere, Laure Gossec, Mélanie Gilson, Xavier Mariette, Maxime Dougados, Thierry Marhadour, Martin Soubrier, Thomas Bardin, Gérard Chalès, P. Richette, Adeline Ruyssen-Witrand, Gaël Mouterde, Christelle Sordet, Françoise Fayet, F. Foissac, L. Euller-Ziegler, Nathalie Balandraud, R.M. Flipo
Publikováno v:
Poster Presentations.
Background Comorbidities including cardiovascular (CV) risk, cancer and osteoporosis are frequent in RA.[1] Objectives To quantify at baseline and 3 years later, the prevalence (at baseline) and incidence (over 3 years) of some selected comorbidities
Publikováno v:
Poster Presentations.
Background Secondary osteoporosis is a comorbidity of Rheumatoid Arthritis (RA). Previous studies have suggested that biological therapies may reduce the rate of generalized bone loss in RA. Most of them focus on the short-term effect of Tumor Necros
Autor:
C. Beauvais, Emmanuelle Dernis, Thierry Marhadour, Xavier Mariette, Sandrine Guis, L. Euller-Ziegler, Adeline Ruyssen-Witrand, P. Richette, S. Pouplin, Gérard Chalès, J. Sibilia, T. Schaeverbeke, Isabelle Chary-Valckenaere, Thomas Bardin, Laure Gossec, Maxime Dougados, F. Foissac, R.M. Flipo, Françoise Fayet, Philippe Gaudin, Martin Soubrier, Gaël Mouterde
Publikováno v:
Poster Presentations.
Background Patients with RA are either more at risk of, or less well screened for, several comorbidities including cardiovascular (CV) risk, cancer, infections and osteoporosis.[1] Recommendations have been developed on how and at what frequency to s
Autor:
Xavier Chevalier, François Bailleul, P. Beks, F. Kemper, L. Euller-Ziegler, J. Jerosch, Thierry Conrozier
Publikováno v:
Archives of Orthopaedic and Trauma Surgery. 129:417-423
Viscosupplementation by repeated intra-articular injections of hyaluronic acid (HA) is used widely in the treatment of symptomatic knee osteoarthritis (OA). The number of injections required can limit the availability of treatment and affect patient
Autor:
Véronique Breuil, Christine M. Albert, Eric Fontas, Olivier Brocq, L. Euller-Ziegler, Christian Roux
Publikováno v:
Revue du Rhumatisme. 74:660-665
Resume Objectif Comparer l'efficacite, en termes de douleur et de fonction d'une, deux ou trois infiltrations d'acide hyaluronique dans la rhizarthrose symptomatique. Methodes Ont ete inclus des patients souffrant d'une rhizarthrose du pouce symptoma